Home › Glioblastoma › Texas
Glioblastoma clinical trials in Texas
33 studies for Glioblastoma are looking for participants at sites in Texas.
Cities in Texas
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- University of Texas - MD Anderson Cancer Center, Houston
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT03970447GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
- Baylor St. Luke's Medical Center, Houston
RecruitingPhase 1
Ages 21 to 70 · All sexes · Updated Sep 30, 2026 · NCT06815432Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- University of Texas Southwestern Medical Center, Dallas
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT05902169A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05303467A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- The University of Texas Southwestern Medical Center - Harold C Simmons Comprehensive Cancer Center, Dallas
- Baylor College of Medicine, Houston
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
- M D Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
- Baylor Scott & White Research Institute, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT05765812Anti-GD2 ADC M3554 in Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06641908A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- NEXT Dallas - Oncology Department, Irving
- START | San Antonio, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06914128Targeted Pediatric High-Grade Glioma Therapy
- Texas Children's Hospital, Houston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388Study of Olutasidenib and Temozolomide in HGG
- Texas Children's Hospital, Houston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
- University of Texas Health Mays Cancer Center, San Antonio
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
- MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07579208Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
- Excel Diagnostics & Nuclear Oncology Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT07733674A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
- The University of Texas M. D. Anderson Cancer Center, Houston
- The University of Texas MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 21, 2026 · NCT06672575Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors
- M D Anderson Cancer Center, Houston
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT04479696Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
- M D Anderson Cancer Center, Houston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT04623931DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UTHealth Houston, Houston
- Baylor College of Medicine, Houston
- The University of Texas Health Science Center at San Antonio, San Antonio
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Texas Children's Hospital, Houston
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Imaging Acetadote Metabolism in Glioblastoma
- University of Texas Southwestern Medical Center, Dallas
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07387666Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Texas Children's Hospital, Houston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT06810544HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- Houston Methodist Neurological Institute, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT03596086Sacituzumab Govitecan in Recurrent Glioblastoma
- Texas Oncology Austin, Austin
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center, San Antonio
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT04559230HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
- Houston Methodist Neurological Institute, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 30, 2026 · NCT03603405SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Dallas
- Massive Bio SYNERGY-AI site, Houston
- Massive Bio SYNERGY-AI site, Temple
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- Mary Crowley Cancer Research, Dallas
- University of Texas Southwestern Medical Center, Dallas
- MD Anderson Cancer Center, Houston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
- Mays Cancer Center, UT Health San Antonio, San Antonio
RecruitingPhase 2
All ages · All sexes · Updated Aug 27, 2025 · NCT04863950Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- UT MD Anderson Cancer Center, Houston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05879367Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 30, 2025 · NCT05460507Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- UT Southwestern Medical Center, Dallas
- The Cancer Therapy and Research Center at UTHSCSA, San Antonio
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Mar 26, 2025 · NCT01906385From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.